## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIESM

OMB APPROVAL OMB Number: 3235-0104 Expires: December 31, 2014 Estimated average burden hours per 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup>	2. Date of Event Requiring	3. Issuer Name <b>and</b> Ticker or Trading Symbol Tokai Pharmaceuticals Inc [TKAI]			
Platt Jon B.	Statement (Month/Day/Year) 09/16/2014	4. Relationship of Reporting Person(s) to Issuer 5. If Amendment, Date of Original Filed (Month/Day/Year)			
(Last) (First) (Middle) C/O TERRIE LOOTENS HYDE, ON THE LINE COMPANY, 393 ARBOR STREET		(Check all applicable) Director X 10% Owner 6. Individual or Joint/Group Filing (Check Applicable Line)   Officer (give title below) Other (specify below) Form filed by One Reporting Person			
(Street) LUNENBURG MA 01462		Form filed by More than One Reporting Person			
(City) (State) (Zip)					

Table I - Non-Derivative Securities Beneficially Owned						
1. Title of Security (Instr. 4)	1		4. Nature of Indirect Beneficial Ownership (Instr. 5)			

Table II - Derivative Securities Beneficially Owned     (e.g., puts, calls, warrants, options, convertible securities)								
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Excercise	5. Ownership Form: Direct (D)	Beneficial Ownership (Instr.	
	Date Exercisable	Expiration Date	Title	Amount or Number of SharesM	Price of Derivative Security	or Indirect (I) (Instr. 5)	5)	
Series B-2 Preferred Stock	(1)	(1)	Common Stock	10,939	<b>\$</b> <sup>(1)</sup>	D		
Series C Preferred Stock	(2)	(2)	Common Stock	38,204	<b>\$</b> <sup>(2)</sup>	D		
Series D-1 Preferred Stock	(3)	(3)	Common Stock	16,696	<b>\$</b> (3)	D		
Series D-2 Preferred Stock	(4)	(4)	Common Stock	3,419	<b>\$</b> <sup>(4)</sup>	D		
Series D-3 Preferred Stock	(5)	(5)	Common Stock	54,074	<b>\$</b> (5)	D		
Series E Preferred Stock	(6)	(6)	Common Stock	459,199	<b>\$</b> (6)	D		

## **Explanation of Responses:**

1. The Series B-2 Preferred Stock is convertible into Common Stock on a 10.47-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

2. The Series C Preferred Stock is convertible into Common Stock on a 10.47-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

3. The Series D-1 Preferred Stock is convertible into Common Stock on a 10.47-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

4. The Series D-2 Preferred Stock is convertible into Common Stock on a 10.47-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

5. The Series D-3 Preferred Stock is convertible into Common Stock on a 10.47-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

6. The Series E Preferred Stock is convertible into Common Stock on a 10.47-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

<u>/s/ Jon B. Platt</u>	<u>09/12/2014</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.